Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 8/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | YAP1 | P46937 | 3/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | TNF | P01375 | 2/20 | 0.39 |
| ▸ | LITAF | Q99732 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18681336 | 0.87 | BTK (0.41) | BTKGPR119TNFLITAFCHEK2 | |
| SCHEMBL21890594 | 0.85 | BTK (0.43) | PRMT5BTKGPR119TNFLITAF | |
| SCHEMBL17121730 | 0.84 | BTK (0.43) | BTKGPR119TNFLITAFCHEK2 | |
| SCHEMBL20506848 | 0.83 | EGFR (0.56) | PRMT5BTKUSP30EGFR | |
| SCHEMBL20506847 | 0.83 | EGFR (0.56) | PRMT5BTKUSP30EGFR | |
| SCHEMBL19037547 | 0.83 | BTK (0.42) | BTKTNFLITAFCHEK2 | |
| SCHEMBL29531255 | 0.82 | HSD11B1 (0.46) | PRMT5BTKUSP30TNFLITAF | |
| SCHEMBL16767775 | 0.82 | HSD11B1 (0.46) | PRMT5BTKUSP30TNFLITAF | |
| SCHEMBL16767773 | 0.82 | HSD11B1 (0.46) | PRMT5BTKUSP30TNFLITAF | |
| SCHEMBL21890766 | 0.81 | BTK (0.39) | BTKUSP30TNFLITAFCHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271938-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20200216419-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. | 2020-07-09 | — | — | US | disclosed |
| US-10590108-B2 | Benzimidazoles for use in the treatment of cancer and inflammatory diseases | CAPELLA THERAPEUTICS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216419-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CHKB, CHKA, CHUK | PRMT5 1903/4885BTK 257/4885YAP1 4050/4885 |
| US-10590108-B2 | Benzimidazoles for use in the treatment of cancer and inflammatory diseases | CHKB, CHKA, CHUK | PRMT5 1903/4885BTK 257/4885YAP1 4050/4885 |
| US-20230271938-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CHKB, CHKA, CHUK | PRMT5 1903/4885BTK 257/4885YAP1 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.